T. Rowe Price Associates’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-17,211
| Closed | -$78K | – | 3133 |
|
|
2025
Q2 | $78K | Hold |
17,211
| – | – | ﹤0.01% | 2941 |
|
|
2025
Q1 | $77K | Buy |
17,211
+3,144
| +22% | +$18.3K | ﹤0.01% | 2874 |
|
|
2024
Q4 | $111K | Sell |
14,067
-8,470
| -38% | -$103K | ﹤0.01% | 2817 |
|
|
2024
Q3 | $297K | Buy |
22,537
+258
| +1% | +$3.27K | ﹤0.01% | 2482 |
|
|
2024
Q2 | $270K | Buy |
22,279
+1,121
| +5% | +$15.1K | ﹤0.01% | 2463 |
|
|
2024
Q1 | $345K | Buy |
21,158
+1,657
| +8% | +$22.3K | ﹤0.01% | 2371 |
|
|
2023
Q4 | $133K | Buy |
19,501
+1,219
| +7% | +$7.05K | ﹤0.01% | 2660 |
|
|
2023
Q3 | $100K | Hold |
18,282
| – | – | ﹤0.01% | 2673 |
|
|
2023
Q2 | $125K | Sell |
18,282
-6,441
| -26% | -$48.3K | ﹤0.01% | 2649 |
|
|
2023
Q1 | $124K | Buy |
24,723
+7,100
| +40% | +$29K | ﹤0.01% | 2642 |
|
|
2022
Q4 | $86K | Buy |
17,623
+915
| +5% | +$6.65K | ﹤0.01% | 2743 |
|
|
2022
Q3 | $241K | Buy |
16,708
+2,285
| +16% | +$37.8K | ﹤0.01% | 2473 |
|
|
2022
Q2 | $218K | Buy |
14,423
+258
| +2% | +$3.01K | ﹤0.01% | 2568 |
|
|
2022
Q1 | $168K | Buy |
+14,165
| New | +$145K | ﹤0.01% | 2751 |
|
|
2019
Q4 | – | Sell |
-837,800
| Closed | -$21.8M | – | 2554 |
|
|
2019
Q3 | $21.8M | Buy |
837,800
+89,449
| +12% | +$2.29M | ﹤0.01% | 1119 |
|
|
2019
Q2 | $17.1M | Buy |
748,351
+108,054
| +17% | +$2.48M | ﹤0.01% | 1221 |
|
|
2019
Q1 | $16.8M | Buy |
640,297
+250,800
| +64% | +$5.51M | ﹤0.01% | 1228 |
|
|
2018
Q4 | $7.92M | Buy |
389,497
+97
| +0% | +$2.23K | ﹤0.01% | 1343 |
|
|
2018
Q3 | $10.3M | Buy |
+389,400
| New | +$9.9M | ﹤0.01% | 1365 |
|
Other funds holding YMAB
T. Rowe Price Associates's YMAB Position: Q3 2025 in Review
T. Rowe Price Associates sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 17,211 shares — an estimated $78K sold.
T. Rowe Price Associates first reported a position in YMAB in Q3 2018 and held it in 19 quarters. The position peaked at $21.8M in Q3 2019. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- T. Rowe Price Associates reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- T. Rowe Price Associates sold 17,211 Y-mAbs Therapeutics shares in Q3 2025, an estimated $78K.
- T. Rowe Price Associates first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 19 quarters.
- T. Rowe Price Associates's Y-mAbs Therapeutics position peaked at $21.8M in Q3 2019.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on T. Rowe Price Associates's 13F filing for Q3 2025, filed 14 Nov 2025.